811 0.905-3.624 0.093 Sex         Male 41 1     Female 27 1.077 0.544-2.134 0.831 Histological type         Well, moderate 47 1     Poor and others 21 1.627 0.813-3.256 0.169 Depth of invasion         T1,2,3 53 1     T4 15 0.691 0.300-1.589 0.385 Selleck Copanlisib Location         Colon 39 1     Rectum 29 1.978 1.005-3.891

0.048* Lymph node metastasis         Absent 25 1     Present 43 2.432 1.098-5.385 0.028* Liver metastasis         Absent 49 1     Present 19 9.764 4.590-20.768 0.000* ANKRD12         High 34 1     Low 34 2.566 1.267-5.201 0.009* n Number of patients, CI confidence interval, * <0.05. Table 3 shows the result of multivariate analysis of in the final model, which included age, histological type, depth of invasion, location, lymph node metastasis and ANKRD12 expression. In this model, the variable of low ANKRD12 expression was an independent prognostic predictor for click here CRC patients (HR, 2.772; 95% CI, 1.065-7.211; P = 0.037; Table 3). Of the patients that were entered in the multivariate analysis, patients with liver metastasis were excluded because the presence of liver metastasis was a strong prognostic factor and was associated with low expression of ANKRD12. Table 3 Multivariate analysis of clinicopathological factors for overall

survival (CRC without liver metastasis)   Hazard ratio 95% CI P value Age (>60/≤60) 0.574 0.208-1.441 0.222 Histological

type (Poor and others/ Well, Moderate) 1.442 0.542-3.836 0.464 Depth of invasion (T4/ T1,2,3) 1.478 0.564-3.873 0.426 Location (Rectum/Colon) 2.002 0.770-5.203 0.154 Lymph node metastasis (present/absent) Epigenetics inhibitor 1.884 0.671-5.295 0.229 ANKRD12 (low/high) 4-Aminobutyrate aminotransferase 2.772 1.065-7.211 0.037* CI confidence interval, * <0.05. Discussion Gene expression regulated by steroid/nuclear hormone receptors (NRs) is crucial in many physiological processes. The activity of NRs is first regulated by ligands [11], as binding of cognate ligands triggers a conformational change that causes receptor activation [12]. Upon ligand binding, co-repressors are released from the receptor, and co-activators are recruited to the activated receptor [13]. Ankyrin repeats-containing cofactor (ANCO) proteins are a family of unique transcriptional co-regulators with dual properties: they interact with both the co-activators and the co-repressors [2]. Ankyrin repeat domain 11 (ANKRD11), also called ANCO-1, is located within the 16q24.3 breast cancer loss of heterozygosity (LOH) region [9] and was a p53 coactivator in breast cancer [10], implying a putative tumour-suppressor role. Ankyrin repeat domain 12 (ANKRD12), also called ANCO-2, is highly related to ANKRD11, especially at the ankyrin repeats and C-terminal domain. However, the clinical significance of ANKRD12 expression in cancer remains unclear.